Home World News Adding PD1 Inhibitor to Neoadjuvant Chemotherapy Significantly Increases the pCR Rate in... World News Adding PD1 Inhibitor to Neoadjuvant Chemotherapy Significantly Increases the pCR Rate in High-Risk, Early-Stage ER-positive, HER2-negative Breast Cancer By Ogkologos - February 12, 2025 1111 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the CheckMate 7FL and KEYNOTE-756 studies Source RELATED ARTICLESMORE FROM AUTHOR Can ctDNA guide treatment intensification in EGFR mutated non-small cell lung cancer? How to select adjuvant endocrine therapy for postmenopausal women with HR-positive early breast cancer? EMA Recommends Extension of Therapeutic Indications for Abiraterone Acetate MOST POPULAR EMA Recommends Extension of Therapeutic Indications for Cabozantinib April 29, 2022 Antitumour Activity of Patritumab Deruxtecan in Heavily Pretreated Patients with Active... October 29, 2025 Ex-NFL Player Pays For 500 Mammograms To Honor Late Mom Who... October 22, 2019 FDA Approves Amivantamab-vmjw with Carboplatin and Pemetrexed for NSCLC with EGFR... September 24, 2024 Load more HOT NEWS Couple Married For 48 Years Shared A Touching Moment As They... A Blood-Based, Multigenomic Signature is an Effective Diagnostic and Has Clinical... 5 Kids Battling Sickle Cell And Cancer Model Their Dream Jobs... FDA Approves Pembrolizumab for Advanced Oesophageal or Gastro-Oesophageal Carcinoma
